Compare Crispr Therapeutics AG (CRSP) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ulta Beauty Inc — how do they compare? Crispr Therapeutics AG trades at $53.83 (market cap $5.23B), while Ulta Beauty Inc trades at $534.99 (market cap $23.27B). The key difference: Ulta Beauty Inc is far larger — about 4.4× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | ULTA | |
|---|---|---|
Market Cap | $5.23B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $706.82 |
52-Week Low | $44.34 | $450.75 |
Enterprise Value | $3.65B | $25.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
ULTA Beauty trades at $548.66, down 2.92% on the day, with strong technical momentum indicated by bullish moving averages and key support at $542. Fundamentally, the company maintains robust profitability with 39.33% gross margins and 47.45% ROE, though recent earnings showed mixed results with a Q4 miss. Revenue growth has been consistent, reaching $11.3B in 2025, while analyst sentiment remains positive with 56.53% buy ratings.
The outlook for ULTA remains favorable with a consensus price target of $618.29 offering 12.7% upside potential. Key opportunities include omnichannel expansion and digital growth initiatives, while risks involve margin pressure from rising costs and competitive retail landscape. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
